|
Basic Characteristics of Mutations
|
|
Mutation Site
|
S31N |
|
Mutation Site Sentence
|
In investigating the frequency of amantadine-resistant IAVs (H3N2) circulating in Iran in 2005-2008, we found that M2 sequences of recently circulating viruses that were amantadine-resistant contained a Ser31Asn mutation. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
M2 |
|
Standardized Encoding Gene
|
M
|
|
Genotype/Subtype
|
H3N2 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Influenza A
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
amantadine |
|
Location
|
Iran |
|
Literature Information
|
|
PMID
|
19537916
|
|
Title
|
Amantadine-resistant influenza A (H3N2) viruses in Iran
|
|
Author
|
Yavarian J,Mokhtari Azad T,Shafiei Jandaghi NZ,Nategh R
|
|
Journal
|
Acta virologica
|
|
Journal Info
|
2009;53(2):135-8
|
|
Abstract
|
Adamantanes have been used for the prophylaxis and treatment of Influenza A virus (IAV) infections worldwide. However, they have limited use because of increasing number of resistant viruses during recent years. In investigating the frequency of amantadine-resistant IAVs (H3N2) circulating in Iran in 2005-2008, we found that M2 sequences of recently circulating viruses that were amantadine-resistant contained a Ser31Asn mutation. Thus, adamantanes should not be used for treatment or prophylaxis of recent IAVs (H3N2) infections. In future, their potential use will depend on the resistance of circulating viruses.
|
|
Sequence Data
|
FJ664618-FJ664632
|